ReviewNature reviews. Cancer2012
Intra-tumour heterogeneity: a looking glass for cancer?
Review in Nature reviews. Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,089 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization
Neuroimaging Study on the Recombination of Brain Motor and Language Function Induced by Glioma
Who cites it
1,089 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Economic Evaluations of Imaging Biomarker-Driven Companion Diagnostics for Cancer: A Systematic Review.Applied health economics and health policy · 2023Pooled it
- Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial.International journal of cancer · 2026Trial
- Beyond a cancer stem cell marker: molecular state dependent functions of CD133 and state targeted therapy.Biomarker research · 2026Review
- Article
- Identification of Novel Transcriptional Alleles in Primary Prostate Cancer Cells and Cancer Stem Cells by Bulk RNA-Seq and Single-Cell RNA-Seq Analyses.Biomolecules · 2026Article
- Multimodal AI and single-cell transcriptomics integrate to construct a histopathological prognostic model for bladder cancer, revealing the RTN3-glycolysis axis in chemoresistance.Experimental hematology & oncology · 2026Article
- A guide to understanding tumour evolution through the lens of population genetics.Nature reviews. Cancer · 2026Review
- Isolation, Structural Characterization, and Potent Leishmanicidal, Anti-Cancer, and Anti-Microbial Activities of a New Diosgenin Glycoside from Malvastrum coromandelianum.Applied biochemistry and biotechnology · 2026Article
- Explainable machine learning for breast cancer prediction in resource-constrained settings: A multi-algorithmic framework integrating shap-based transparency with clinical decision support.PLOS digital health · 2026Article
- Review
- ETS1 Orchestrates a Hybrid EMT Program Driving Metastasis and Immune Evasion.Cancer research · 2026Article
- Article
- Targeting Spatiotemporal Heterogeneity of oncomiRNAs: A New Frontier in Cancer Therapy.Cancer reports (Hoboken, N.J.) · 2026Review
- Metabolic buffering restricts phenotype switching in melanoma.The EMBO journal · 2026Article
- Noninvasive Characterization of Tumor Heterogeneity in HNSCC: From Clinical Utility to Biological Correlates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Counterfactual Diffusion Modeling Enables Spatially Targeted Reprogramming of Tissue Microenvironments.Biology · 2026Article
- Beyond Color: Hybrid Vibrational-Electronic Broadband Coherent Anti-Stokes Raman Scattering for Molecularly Informed Digital Pathology.Analytical chemistry · 2026Article
- Long-term competition experiments reveal limited adaptive evolution in human cell lines.Scientific reports · 2026Article
- Review
- scRADAR: Dissecting intratumoral drug response heterogeneity at single-cell resolution via mechanism-guided prototype routing.PLoS computational biology · 2026Article
1,029 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Populations of tumour cells display remarkable variability in almost every discernable phenotypic trait, including clinically important phenotypes such as ability to seed metastases and to survive therapy. This phenotypic diversity results from the integration of both genetic and non-genetic influences. Recent technological advances have improved the molecular understanding of cancers and the identification of targets for therapeutic interventions. However, it has become exceedingly apparent that the utility of profiles based on the analysis of tumours en masse is limited by intra-tumour genetic and epigenetic heterogeneity, as characteristics of the most abundant cell type might not necessarily predict the properties of mixed populations. In this Review, we discuss both genetic and non-genetic causes of phenotypic heterogeneity of tumour cells, with an emphasis on heritable phenotypes that serve as a substrate for clonal selection. We discuss the implications of intra-tumour heterogeneity in diagnostics and the development of therapeutic resistance.
Indexed as
Identifiers
22513401What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.